^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | iopofosine I-131 (CLR 131) (DNA inhibitor, Ionizing radiation emitter) |
| Direction: | Sensitive |
Evidence:
Title:
Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia
Published date:
05/26/2020
Excerpt:
Cellectar Bioscience...today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) in patients having received two prior treatment regimens or more.
